Status:
RECRUITING
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
Lead Sponsor:
Vanderbilt University Medical Center
Collaborating Sponsors:
University of Louisville
Boston University
Conditions:
Microtia
Dysbiosis
Eligibility:
All Genders
18-89 years
Phase:
PHASE2
Brief Summary
Among people living with HIV, heavy drinking increases the risk of heart disease and death. Studies suggest that alcohol changes the number and kind of bacteria in your gut and these changes increase ...
Detailed Description
Among people living with HIV (PLWH), heavy drinking increases the risk of cardiovascular disease (CVD) and death. Data suggest that alcohol-associated gut dysbiosis partially drives this risk. Whether...
Eligibility Criteria
Inclusion
- HIV infected
Exclusion
- Not fluent in English
Key Trial Info
Start Date :
September 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2027
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05288790
Start Date
September 18 2023
End Date
February 28 2027
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232